Provectus Biopharma approves up to $5M convertible loan; CFO invests $200K

PROVECTUS BIOPHARMACEUTICALS, INC.

Board approved financing term sheet for up to $5,000,000 unsecured convertible loan.
Loan bears 8% interest, due in 12 months; convertible into Series D-1 Preferred at $2.862/share (each converts to 10 common shares).
On Aug 16, 2021, CFO Heather Raines invested $200,000 via a 2021 Note under the same terms.
Proceeds to fund drug discovery/development and general administrative expenses.
Issuance exempt from registration under Section 4(a)(2) or Rule 506 of the Securities Act.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.